BioNTech stock plunges 22% after founders announce surprise exit
BioNTech Stock Plunges Amid Founders' Departure—Is the Rebound Just a Dead-Cat Bounce?
Shares of COVID-19 vaccine pioneer BioNTech have come under heavy pressure in recent weeks following reports that co-founders Ugur Sahin and Özlem Türeci will leave the company by year-end to launch their own firm.
Volatile Recovery After Sharp Sell-Off
Their departure not only leaves a major void in the research division of the Mainz-based biotech powerhouse but has also sparked significant uncertainty in the markets. The stock initially plummeted by over 22 percent before rebounding roughly 20 percent in the days that followed.
Since midweek, however, the share price has resumed its downward trajectory. This raises the possibility that the recent recovery was nothing more than a so-called dead-cat bounce—a brief, superficial uptick in a steadily declining trend, akin to the idea that even a dead cat will bounce if dropped from a great height. If true, the rally lacks real momentum, and the stock may continue its slide.
Where Is BioNTech Headed Next?
The latest dip below the $90.00 mark is an early warning sign. The next key support level lies between $85.21 and $85.40. If the stock fails to hold there, it could retest the $80.00 threshold.
A sustained drop below $80 would break the sideways trading range that has held since mid-2023—potentially opening the door to far steeper declines.
